ALKEM vs BLISSGVS: Stock Comparison

Alkem Laboratories Limited vs Bliss GVS Pharma Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Alkem Laboratories Limited is the larger company by market capitalisation. Alkem Laboratories Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Bliss GVS Pharma Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alkem Laboratories Limited and Bliss GVS Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ALKEM is more favourable on 9 of 13 scored metrics and BLISSGVS on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ALKEM is the larger company
₹66,765 Cr vs ₹4,792 Cr
P/E Ratio
ALKEM has a lower P/E
29.54x vs 38.27x
P/B Ratio
BLISSGVS has a lower P/B
4.14x vs 4.92x
EPS
ALKEM has higher earnings per share
₹192.78 vs ₹11.99
Dividend Yield
ALKEM has a higher dividend yield
0.35% vs 0.19%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs 14.6%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs -22.7%
Qtr Sales Growth
ALKEM has stronger quarterly sales growth
14.6% vs 13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricALKEMBLISSGVS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricALKEMBLISSGVS
Live Price₹5,585.5₹527.1
Day Change-1.69%0.68%
Volume96,2693.93 L
52-Week High₹5,933.5₹553
52-Week Low₹4,738.5₹118
Distance from 52W High-5.87%-4.68%

Valuation

MetricALKEMBLISSGVS
Market Cap₹66,765 Cr₹4,792 Cr
P/E Ratio29.54x38.27x
P/B Ratio4.92x4.14x
EPS₹192.78₹11.99
Book Value₹1,155.47₹107.21
Dividend Yield0.35%0.19%

Growth

MetricALKEMBLISSGVS
Revenue Growth (TTM YoY)14.6%29.8%
EPS Growth (TTM YoY)-22.7%124.7%
Qtr Sales Growth14.6%13%
Qtr Profit Growth2.04%108%

Profitability & Leverage

MetricALKEMBLISSGVS
ROE18.9%0%
ROCE21.2%11.7%
Net Margin15.65%13.93%
Operating Margin20.4%12.82%
Debt to Equity0.15x1.77x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricALKEMBLISSGVS
Promoter Holding49.7% 1.5 pp35.36%
FII Holding10.42% 0.26 pp10.45% 4.09 pp
DII Holding22.63% 1.23 pp5.04% 0.74 pp
Public Holding17.25%49.15% 4.83 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alkem Laboratories Limited and Bliss GVS Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.